Articles tagged with Multiple Sclerosis
The National Multiple Sclerosis Society has launched a $100 million brain repair initiative aimed at restoring nerve function in people with MS. The program will fund research into new disease models, advanced MRI monitoring tools, and human clinical trials.
A new study published by the Mayo Clinic research team found that many MS patients experience mild disability over time, with 71 of 99 walking unassisted in 1991 still doing so in 2001. The study also showed that only 20% of patients who didn't need a wheelchair in 1991 required one 10 years later.
A study found that women taking high doses of vitamin D supplements were 40% less likely to develop multiple sclerosis. Vitamin D levels in the blood prior to onset of MS should be measured in future studies.
Researchers discovered levetiracetam reduces phasic spasticity in MS patients, improving balance and walking difficulties. The medication also shows promise in treating other symptoms associated with the disease.
A study found that a single nucleotide polymorphism in the CD24 gene is associated with an increased risk of developing multiple sclerosis. The research suggests that the protein encoded by this gene may be a valuable target for new drugs to treat the disease.
A new MRI technique using whole brain N-acetylaspartate (WBNAA) measures the amount of NAA in the brain, which decreases with MS disease progression. This method is more sensitive and specific than current markers, enabling earlier treatment monitoring and drug development for MS patients.
The UK trial found no objective evidence that cannabis benefits people with multiple sclerosis, but a majority of patients reported improved symptoms. The study involved over 600 patients and assessed the effectiveness of cannabinoids in reducing muscle stiffness and improving overall wellbeing.
A large-scale trial found no major effect of cannabinoids on spasticity but showed small reductions in walking time and subjective improvements in patients. The study suggests that cannabinoids may be clinically useful in treating MS symptoms, particularly when other treatments fail.
Researchers found that IFN-beta-1a initiates different patterns of genetic expression in MS patients, which could lead to better treatment outcomes. The study's findings suggest that gene expression profiling and pharmacodynamics may enable improved, possibly individualized, treatment regimens for MS patients.
A recent study published by the American Academy of Neurology found that smoking significantly increases the risk of developing multiple sclerosis (MS), regardless of age or education level. The study examined over 22,000 people and found that smokers were 1.81 times more likely to develop MS than non-smokers.
Researchers used computer-assisted MRI technology to visualize gray matter structures in the brain of MS patients, finding T2 hypointensity associated with iron deposits. The study found correlations between T2 hypointensity and impaired walking ability and cognitive impairment, suggesting a new potential target for treatment.
The study found that initiating Avonex treatment immediately after MS symptoms appeared reduced the development of clinically definite MS by 35% and relapses by 48% compared to delayed initiation. Early intervention also led to higher likelihood of being classified as clinically stable between years four and five.
A new study suggests that advanced MRI scans can diagnose multiple sclerosis more quickly and accurately than traditional methods. The technology uses sophisticated imaging to detect white matter abnormalities in the brain, providing doctors with definitive evidence of injuries over time.
The American Academy of Neurology has introduced a new guideline that suggests MRI scans can be used to predict the development of multiple sclerosis in individuals who have had a single occurrence of MS symptoms. This allows for earlier diagnosis and treatment, which can help reduce disease activity and severity.
Researchers at the MNI have made a groundbreaking discovery about netrins, proteins that guide nerve cell axons to their target in the developing nervous system. The study suggests that netrin acts as a repellent cue for migrating oligodendrocytes, which could lead to new therapies for Multiple Sclerosis.
Researchers investigate targeting pericytes and endothelial cells with kinase inhibitors to treat cancer and autoimmune diseases. PDX1 levels also play a crucial role in islet survival and diabetes development, while Factor H's anti-inflammatory properties are explored for hemolytic uremic syndrome treatment.
New research presented at the AAN Annual Meeting includes promising treatments for MS, potential therapeutic targets for worsening ataxia in ALS, and a connection between Chlamydia infection and increased stroke risk. Statins also show promise in reducing cognitive decline and improving recovery from stroke.
Researchers found significant improvement in fatigue among MS patients who participated in yoga and exercise groups compared to a waiting list group. The study suggests that activity interventions may have a positive impact on quality of life for people with multiple sclerosis.
Researchers have found that simvastatin, a cholesterol-lowering medication, reduces the number and volume of active MS lesions. The study suggests statins may have therapeutic value in treating multiple sclerosis, but further studies are needed to confirm its effectiveness.
A study found that Keppra, when used in combination with conventional treatments, provided significant pain relief for multiple sclerosis (MS) patients. Over half of the participants showed marked improvement and continued treatment with Keppra.
The National Multiple Sclerosis Society has awarded $2.48 million to advance research on multiple sclerosis through five collaborative centers. These centers are focused on genetic underpinnings of MS, tissue repair and diagnostic technology, including the use of haplotype mapping and diffusion tensor MR imaging.
A review of seven trials found that interferon may reduce exacerbations in relapsing-remitting multiple sclerosis patients in the first year, but its long-term effects are uncertain. Common side effects and toxic effects also occurred.
A Phase II study published in NEJM found that natalizumab significantly reduced new gadolinium-enhancing lesions by up to 93% and the number of patients experiencing relapses by 50%. The treatment was well-tolerated, with common adverse events including infection and rash.
In the Phase II study, natalizumab demonstrated higher rates of clinical remission compared to placebo at multiple time points. The highest rate of remission was observed in the dual 3 mg/kg dose group, with a maximal response of 71%.
Acorda Therapeutics has received a Phase 2 grant from the National Institutes of Health (NIH) to develop a new treatment approach for multiple sclerosis (MS). The company's antibodies, sHIgM22 and sHIgM46, have shown promise in stimulating myelin regrowth in animal models.
Researchers explore the role of statins in preventing CNS leucocyte accumulation in multiple sclerosis, a condition that increases dementia risk. A review on mild cognitive impairment highlights the urgency to address these disorders.
Researchers have discovered a protein in the eye that can successfully treat an autoimmune disease by converting conventional T cells into regulatory T cells. The study found significant reduction in uveitis severity and prevention of disease onset in mice models.
Women with relapsing-remitting MS experienced an average of 2.6 MS exacerbations that lasted 29 days, with 85% linked to stressful life events in the prior six weeks. Stressors from various sources and severity levels were equally associated with flare-ups.
Acorda Therapeutics has received the L.W. Freeman Award for its pioneering work in regenerative therapies and functional improvements for spinal cord injury patients. The company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and aims to restore function in people with SCI.
Researchers found that a cholesterol drug, atorvastatin, reduced paralysis and suppressed attacks in mice with multiple sclerosis. The study suggests that the drug could prevent progression to definite multiple sclerosis in individuals who have had a first attack.
Researchers have developed a new vaccine that amplifies the production of beneficial antibodies to combat IP-10, a protein responsible for autoimmune disease progression. The vaccine rapidly suppressed experimentally induced rheumatoid arthritis and MS, offering potential relief for millions.
The Lancet Neurology recently published a series of articles discussing the latest evidence on Alzheimer's disease, including preventative anti-inflammatory clinical trials and the role of secretases in producing amyloid-beta peptide. Researchers argue that these approaches hold promise for preventing or slowing the onset of the disease.
Researchers found that statins modify immune system molecules involved in MS progression, exhibiting potent anti-inflammatory effects. Statin therapy may serve as a useful standalone or add-on treatment for patients with MS.
Researchers at Ohio State University have developed a peptide treatment that inhibits experimental autoimmune encephalomyelitis (EAE) and suppresses the onset of multiple sclerosis-like symptoms. The treatment targets T cells by binding to CD80, preventing their activation and expansion in disease.
Fampridine-SR shows promise in reducing spasticity and improving bladder, bowel, and sexual function in patients with chronic SCI. The Phase 3 trial enrolls 360 patients at leading clinical centers in the US and Canada.
Researchers at JCI Journals have made significant strides in understanding the biological function and clinical relevance of copolymers. The study's findings hold promise for developing new treatments for various human diseases.
Researchers have found that two diabetes medications, thiazolidinediones, can prevent the development of multiple sclerosis in mice and reduce symptoms. The study suggests that these insulin-sensitizing drugs may also be effective in treating other neurologic diseases such as Alzheimer's and Parkinson's.
Scientists at PNNL and the Institute of Immunological Engineering have created unique humanized antibodies to gamma interferon, a protein that triggers autoimmune conditions. These fully humanized antibodies may provide long-term treatment for autoimmune diseases.
Researchers at Mayo Clinic discovered a link between an enzyme called MSP and multiple sclerosis tissue damage, which could lead to new treatment options. The study found that excess MSP promotes demyelination, but also contributes to proper oligodendroglia function when functioning normally.
Researchers at the University at Buffalo's Buffalo Neuroimaging Analysis Center are providing new insights into multiple sclerosis using advanced MRI brain imaging methods. They have found that the brain's gray matter, where higher functioning is centered, is involved in MS and has identified a potential target for treatment.
A large randomized clinical trial found that synthetic THC and plant-extract marijuana derivatives were safe but showed no improvement in spasticity symptoms for multiple sclerosis patients. Side effects, particularly with the plant-extract, were common and may limit potential dosages.
Researchers at Stanford Medicine have identified hundreds of new genes involved in multiple sclerosis (MS) progression. The study found genes expressed differently in acute and chronic attacks, including those associated with pregnancy and allergic responses, which could lead to new treatment strategies.
A 2-year study found that high-dose interferon beta-1b significantly reduced relapse rates and new brain lesions in patients with relapsing-remitting multiple sclerosis compared to interferon beta-1a. The treatment also showed a strong association between MS and type-1 diabetes in the Sardinian population.
Researchers found that lipitor prevented both acute and relapsing forms of multiple sclerosis-like disease in mice, reversing symptoms in those with chronic relapsing form. Lipitor also reduced CNS inflammation by inducing anti-inflammatory cytokines and suppressing pro-inflammatory cytokines.
A six-month pilot study found that Ginkgo biloba improved performance on neuropsychological tests in patients with mild multiple sclerosis. About 50% of Americans with MS experience cognitive problems, and the herb may show a beneficial effect on attention, memory, and functioning.
Researchers found that mitoxantrone induction therapy significantly reduced disease activity in MS patients, with a 76% relapse-free rate at one year and 64% at four years. The annual relapse rate decreased by nearly 90% following treatment.
A new autologous stem cell transplantation treatment has shown promising results in stabilizing the disability of 26 people with severe multiple sclerosis. The study found that 20 patients remained stable, while six showed mild improvement, with only three experiencing new brain lesions at one year after the transplant.
Researchers analyzed seasonal changes in immune system activity among 28 MS patients, finding more activated T-cells during autumn months. However, no significant variation was detected in lesions or relapse rates, challenging previous theories on the topic.
Researchers found that Copaxone, a commonly used MS treatment, stimulates CD8 cells in patients, whereas untreated patients show weaker responses. This new approach enables effective evaluation of both CD4 and CD8 cells taken directly from patients.
A new study has discovered subtle normal appearing brain tissue changes in first-degree relatives of patients with familial and sporadic Multiple Sclerosis (MS). These changes were not detectable using conventional MRI, but a new test called magnetization transfer imaging revealed the damage.
A new study has found that the medication modafinil can effectively alleviate fatigue in patients with multiple sclerosis. The drug was shown to improve symptoms in 75-90% of patients, with significant benefits reported at a dosage of 200mg per day.
A study suggests that minocycline, a common antibiotic, could be a potential therapy for multiple sclerosis. The drug showed promising results in rats with autoimmune encephalomyelitis, reducing neurologic dysfunction and disease severity.
Researchers found osteopontin is present in higher levels in the brains of individuals with MS and mice models. Osteopontin's presence may accelerate disease progression, prompting efforts to block its effects.
Researchers at Stanford and UCSF have identified osteopontin as a key gene in the progression of multiple sclerosis, with findings suggesting its expression levels are related to disease severity. The study also revealed that osteopontin-deficient mice experienced significantly less severe symptoms and higher remission rates.
Researchers found that a cooling vest improved MS patient symptoms by reducing muscle strength and fatigue, as well as balance. Nitric oxide levels decreased significantly in patients receiving active cooling.
A team of researchers at Yale University successfully transplants Schwann cells into a patient's brain to repair damaged nerve fibers in Multiple Sclerosis. The procedure aims to restore normal function and has the potential to benefit millions of people affected by MS and other demyelinating diseases.
Scientists successfully used frozen human nerve cells to repair damaged spinal cords in an animal model of multiple sclerosis. The method may one day allow patients to use their own cells to treat demyelinating diseases.
A new therapy effectively treats a disease similar to multiple sclerosis in monkeys by targeting T cells that cause the disease. The approach could soon be tested against MS and other autoimmune diseases in humans, offering potential for improved treatment options.
A new study published in Neurology reveals that multiple sclerosis (MS) patients lose cognitive ability and report increased mental fatigue after repeated testing. Researchers attribute this decline to fluctuations in glucose supply and metabolism, which affect brain performance.
Scientists at Brookhaven National Laboratory are conducting a three-year study using the powerful MRI scanner to look for early signs of MS. The study aims to understand the disease process and potentially lead to more effective diagnosis and treatment.